Identification of group A Streptococcus antigenic determinants upregulated in vivo

Infection and Immunity

Volumn 73, Issue 9, 2005, Pages 6026-6038

  Salim, Kowthar Y ^a   Cvitkovitch, Dennis G ^a   Chang, Peter ^a   Bast, Darrin J ^a   Handfield, Martin ^b   Hillman, Jeffrey D ^b,c   De Azavedo, Joyce C S ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

^c iviGene Corp   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPITOPE; GENE PRODUCT; LIPOPROTEIN; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 1A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; BACTERIAL VIRULENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; GENE EXPRESSION; GENE IDENTIFICATION; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; SEQUENCE HOMOLOGY; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TRANSLATION INITIATION; UPREGULATION; VIBRIO VULNIFICUS;

ANIMALS; ANTIGENS, BACTERIAL; EPITOPES; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; GENOMIC LIBRARY; HUMANS; MICE; MICE, INBRED HRS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; UP-REGULATION;

EID: 23944524893     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.9.6026-6038.2005     Document Type: Article

References (49)

1. Berry, A. M., and J. C. Paton. 1996. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect. Immun. 64:5255-5262.
2. Betschel, S. D., S. M. Borgia, N. L. Barg, D. E. Low, and J. C. de Azavedo. 1998. Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S. Infect. Immun. 66:1671-1679.
3. Cao, S. L., A. Progulske-Fox, J. D. Hillman, and M. Handfield. 2004. In vivo induced antigenic determinants of Actinobacillus actinomycetemcomitans. FEMS. Microbiol. Lett. 237:97-103.
4. Cheng, S. L., C. J. Clancy, M. A. Checkley, M. Handfield, J. D. Hillman, A. Progulske-Fox, A. S. Lewin, P. L. Fidel, and M. H. Nguyen. 2003. Identification of Candida albicans genes induced during thrush offers insight into pathogenesis. Mol. Microbiol. 48:1275-1288.
5. Choudhry, A. E., T. L. Mandichak, J. P. Broskey, R. W. Egolf, C. Kinsland, T. P. Begley, M. A. Seefetd, T. W. Ku, J. R. Brown, M. Zalachain, and K. Ratnam. 2003. Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections. Antimicrob. Agents Chemother. 47:2051-2055.
6. Crowther, J. R. 2001. The ELISA guidebook, p. 45-82. Humana Press, Inc., New York, N.Y.
7. Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511.
8. Deb, D. K., P. Dahiya, K. K. Srivastava, R. Srivastava, and B. S. Srivastava. 2002. Selective identification of new therapeutic targets of Mycobacterium tuberculosis by IVIAT approach. Tuberculosis 82:175-182.
9. Demers, B., A. E. Simor, H. Vellend, P. M. Schlievert, S. Byrne, F. Jamieson, S. Walmsley, and D. E. Low. 1993. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin. Infect. Dis. 16:792-800.
10. Fischetti, V. A. 2000. Vaccine approaches to protect against group A streptococcal pharyngitis, p. 96-104. In R. P. Fischetti, P. P. Novick, J. J. Ferretti, J. J. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, D.C.
11. Freeman, W. M., S. J. Walker, and K. E. Vrana. 1999. Quantitative RT-PCR: pitfalls and potential. BioTechniques 26:112-115.
12. Fuller, J. D., A. C. Camus, C. L. Duncan, V. Nizet, D. J. Bast, R. L. Thune, D. E. Low, and J. C. S. de Azavedo. 2002. Identification of a Streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus pneumonias disease. Infect. Immun. 70:5730-5739.
13. Ghuysen, J. M. 1991. Serine beta-lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 45:37-67.
14. Graham, M. R., L. M. Smoot, C. A. Lux Migliaccio, K. Virtaneva, D. E. Sturdevant, S. F. Porcella, M. J. Federle, G. J. Adams, J. R. Scott, and J. M. Musser. 2002. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc. Natl. Acad. Sci. USA 99:13855-13860.
15. Handfield, M., and R. C. Levesque. 1999. Strategies for isolation of in vivo expressed genes from bacteria. FEMS. Microbiol. Rev. 23:69-91.
16. Handfield, M., J. Brady, A. Progulske-Fox, and J. D. Hillman. 2000. IVIAT: a novel method to identify microbial genes expressed specifically during human infections. Trends Microbiol. 8:336-339.
17. Handfield, M., T. Seifert, and J. D. Hillman. 2003. In vivo expression of bacterial genes during human infections. Methods Mol. Med. 71:225-242.
18. Hang, L., M. John, M. Asaduzzaman, E. A. Bridges, C. Vanderspurt, T. J. Kirn, K. R. Taylor, J. D. Hillman, A. Progulske-Fox, M. Handfield, E. T. Ryan, and S. B. Calderwood. 2003. Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc. Natl. Acad. Sci. USA 100:8508-8513.
19. Hautefort, I., and J. C. Hinton. D. 2000. Measurement of bacterial gene expression in vivo. Phil. Trans. R. Soc. Lond. B 355:601-611.
20. Higgins, C. F. 2001. ABC transporters: physiology, structure, and mechanisms-an overview. Res. Microbiol. 152:205-210.
21. Hoge, C. W., B. Schwartz, D. F. Talkington, R. F. Breiman, E. M. MacNeill, and S. J. Englender. 1993. The changing epidemiology of invasive group A streptococcal infections and the emergence of toxic shock-like syndrome: a retrospective population-based study. JAMA 269:384-389.
22. Jones, A. L., R. H. V. Needham, A. Clancy, K. M. Knoll, and C. E. Rubens. 2003. Penicillin-binding proteins in Streptococcus agalactiae: a novel mechanism for evasion of immune clearance. Mol. Microbiol. 47:247-256.
23. Kaul, R., A. McGeer, D. E. Low, K. Green, B. Schwartz, et al. 1997. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventyseven cases. Am. J. Med. 103:18-24.
24. Kim, Y. R., S. E. Lee, C. M. Kim, S. Y. Kim, K. E. Shin, D. H. Shin, S. S. Chung, H. E. Choy, A. Progulske-Fox, J. D. Hillman, M. Handfield, and J. H. Rhee. 2003. Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients. Infect. Immun. 71:5461-5471.
25. Kiska, D. L., B. Thiede, J. Caracciolo, M. Jordan, D. Johnson, E. L. Kaplan, R. P. Gruninger, J. A. Lohr, P. H. Gilligan, and F. W. Denny. 1997. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J. Infect. Dis. 176:992-1000.
26. Lau, P. C., C. K. Sung, J. H. Lee, D. A. Morrison, and D. G. Cvitkovitch. 2002. PCR ligation mutagenesis in transformable streptococci: application and efficiency. J. Microbiol. Methods 49:193-205.
27. Lazaveric, V., P. Margot, B. Soldo, and D. Karamata. 1992. Sequencing and analysis of the Bacillus subtilis lytRABC divergon: a regulatory unit encompassing the structural genes of the N-acetylmuramoyl-L-alanine amidase and its modifier. J. Gen. Microbiol. 138:1949-1961.
28. Lei, B., M. Liu, G. L. Chesney, and J. M. Musser. 2003. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J. Infect. Dis. 189:79-89.
29. Lei, B., S. Mackie, S. Lukomski, and J. M. Musser. 2000. Identification and immunogenicity of group A Streptococcus culture supernatant proteins. Infect. Immun. 68:6807-6818.
30. McAuliffe, O., R. P. Boss, and C. Hill. 2001. Lantibiotics: structure, biosynthesis, and mode of action. FEMS. Microbiol. Rev. 25:285-308.
31. Medina, E., O. Goldmann, M. Rohde, A. Lengeling, and G. S. Chhatwals. 2001. Genetic control of susceptibility to group A streptococcal infection in mice. J. Infect. Dis. 184:846-852.
32. Musser, J. M., V. Kapur, S. Kanjilal, U. Shah, D. M. Musher, N. L. Barg, K. H. Johnston, P. M. Schlievert, J. Henrichsen, D. Gerlach, R. M. Rakita, A. Tanna, B. D. Cookson, and J. C. Huang. 1993. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (scarlet fever toxin). J. Infect. Dis. 167:337-346.
33. Musser, J. M., V. Kapuir, J. Szeto, X. Pan, D. S. Swanson, and D. R. Martin. 1995. Genetic diversity and relationship among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect. Immun. 63:994-1003.
34. Ogunniyi, A. D., P. Giammarinaro, and J. C. Paton. 2002. The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are up-regulated and differentially expressed in vivo. Microbiology 148:2045-2053.
35. Okada, N., A. P. Pentland, P. Falk, and M. G. Caparon. 1994. M protein and protein F act as important determinants of cell-specific tropism of Streptococcus pyogenes in skin tissue. J. Clin. Investig. 94:965-977.
36. Rock, C. O., R. B. Calder, M. A. Karim, and S. Jackowski. 2000. Pantothenate kinase regulation of the intracellular concentration of coenzyme A. J. Biol. Chem. 275:1377-1383.
37. Runar, R., M. M. Beerthuyzen, W. M. de Vos, P. E. J. Saris, and O. P. Kuipers. 1999. Effects of gene disruptions in the nisin gene cluster of Lactococcus lactis on nisin production and producer immunity. Microbiology 145:1227-1233.
38. Sawers, G. 2001. A novel mechanism controls anaerobic and catabolite regulation of the Escherichia coli tdc operon. Mol. Microbiol. 39:1285-1298.
39. Siegers, K., and K. D. Entian. 1995. Genes involved in immunity to the lantibiotic nisin produced by Lactcoccus lactis 6F3. Appl. Environ. Microbiol. 61:1082-1089.
40. Smith, H. 2000. Questions about the behavior of bacterial pathogens in vivo. Phil. Trans. R. Soc. Lend. B 355:551-564.
41. Smoot, L. M., J. C. Smoot, M. R. Graham, G. A. Somerville, D. E. Sturdevant, C. A. Lux Migliaccio, G. L. Sylva, and J. M. Musser. 2001. Global differential gene expression in response to growth temperature alteration in group A Streptococcus. Proc. Natl. Acad. Sci. USA 98:10416-10421.
42. Stromberg, A., V. Romanus, and L. G. Burman. 1991. Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J. Infect. Dis. 164:595-598.
43. Sutcliffe, I. C., and R. R. B. Russell. 1995. Lipoproteins of gram-positive bacteria. J. Bacteriol. 177:1123-1128.
44. Talkington, D. F., B. G. Brown, J. A. Thorpe, A. Koenig, and H. Russell. 1996. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesion A (PsaA). Microb. Pathog. 21:17-22.
45. Vlaminckx, B. J. M., E. M. Mascini, J. Schellekens, L. M. Schouls, A. Paauw, A. C. Fluit, R. Novak, J. Verhoef, and F. J. Schmitz. 2003. Site-specific manifestations of invasive group A streptococcal disease: type distribution and corresponding patterns of virulence determinants. J. Clin. Microbiol. 41:4941-4949.
46. Voyich, J. M., D. E. Sturdevant, K. R. Braughton, S. D. Kobayashi, B. Lei, K. Virtaneva, D. W. Dorward, J. M. Musser, and F. R. DeLeo. 2003. Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes. Proc. Natl. Acad. Sci. USA 100:1996-2001.
47. Wilson, K. 1994. Preparation of genomic DNA from bacteria, p. 2.4.1-2.4.5. In F. M. Ausubel, R. Brent, E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 1. John Wiley & Sons, Inc., New York, N.Y.
48. Yoshida, A., and H. K. Kuramitsu. 2002. Multiple Streptococcus mutans genes are involved in biofilm formation. Appl. Environ. Microbiol. 68:6283-6291.
49. Zysk, G., R. J. M. Bongaerts, E. Thoren, G. Bethe, R. Hakenbeck, and H. Heinz. 2000. Detection of 23 immunogenic pneumococcal proteins using convalescent-phase serum. Infect. Immun. 68:3740-3743.